2025-06-05-Jefferies-Aclaris（ACRS）_ACRS_JEF_2025年医疗会议_创新与整合丰富的产品线开发进展顺利_7页_109kb

Aclaris Therapeutics (ACRS) Equity Research Summary

• Company Overview: Aclaris Therapeutics is a clinical-stage biotechnology company focused on precision immuno-inflammatory programs, including the acquisition of Confluence, with a lead portfolio in treatments for diseases like rheumatoid arthritis and atopic dermatitis.

• Pipeline Highlights:

  • ATI-450 (TSLP Inhibitor): Currently in Phase 2 study for atopic dermatitis and respiratory diseases. Co. aims for Ph2b data in Alzheimer's disease (AD) by 2H26, with plans to seek partners for respiratory indications. The AD trial is placebo-controlled, designed to address biases from earlier single-arm results. Positive data from collaborator CTTQ in severe asthma and CRSwNP in China show enhanced potency, supporting future partnerships and potentially influencing regulatory discussions for late-phase trials, though alignment with regulators is pending.
  • '2138 (ITK/JAK3 Inhibitor): Ph2a trial in AD is ongoing, with top-line data expected in June 2025. Co. may initiate Ph2 development in alopecia areata (AA) due to its potential receptiveness to the JAK3 mechanism. Preclinical work on next-gen ITK inhibitors and bispecific antibodies is underway, with IND filings planned for 2026.
  • '052 (TSLP/IL4R): Ph1a trial set to begin in 2Q25 for safety, PK, and PD studies, followed by Ph1b POC in an undisclosed indication (respiratory or AD) by year-end. Key insight: The POC portion may test 2 indications (potentially AD and respiratory) due to extended cash runway.
  • Financial Status: Cash runway extends to 1H28, supporting current clinical plans and operating at a low burn rate to extend funding.

• Analyst Recommendation: Jefferies Equity Research rates ACRS as "BUY" with a price target of $7.00, implying a 335% upside from the prior close. Key risks include clinical trial failures, regulatory hurdles, and commercial uncertainties, while valuation is DCF-based.

• Key Insights: Growing inbound interest from potential partners for respiratory development of ATI-450; positive CTTQ data provide clinical evidence of enhanced potency, but regulatory alignment for late-phase trials is not yet confirmed. The company's cash runway ensures coverage for planned programs and partnerships.

Note: This summary is based on the provided report and does not constitute investment advice.